Related Experiment Videos
Progressive supranuclear palsy syndrome induced by clebopride
Jaume Campdelacreu1, Hatice Kumru, Eduard Tolosa
1Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Malalties del Sistema Nerviós (ICMSN), Hospital Clínic Universitari, Barcelona, Spain.
Summary
A patient developed progressive supranuclear palsy (PSP)-like symptoms while taking clebopride, a drug with antidopaminergic effects. Symptoms resolved after discontinuing clebopride, suggesting a drug-induced syndrome.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease.
- Clebopride (CLB) is a prokinetic agent with central antidopaminergic properties.
Observation:
- A patient presented with clinical and neurophysiological signs consistent with PSP syndrome.
- The patient was concurrently receiving clebopride for gastrointestinal issues.
Findings:
- The PSP-like syndrome and associated signs showed progressive improvement after clebopride withdrawal.
- This suggests a potential causal link between clebopride and the observed PSP-like presentation.
Implications:
- This case highlights a potential iatrogenic cause of PSP-like syndromes.
- Antidopaminergic drugs, such as clebopride, may unmask or induce neurological symptoms resembling PSP.
- Further investigation into the neurotoxic potential of antidopaminergic agents is warranted.